Dr. Priyom Bose

Online analysis of Long COVID narratives

In a new study published in Digital Health, scientists built a knowledge base starting with the patient. Using social media data, they aimed to understand what rehabilitation strategies could be adopted for those living with Long COVID.

Effectiveness of COVID-19 booster vaccination strategies in partially vaccinated populations

Study reveals that the most beneficial vaccination strategy is to distribute all available doses of COVID-19 vaccines predominantly for primary vaccinations and the remaining doses for boosters.

Novel waveform-based approach to determine the propensity of betacoronaviruses to infect humans

Scientists attempt to understand the evolution of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2.

Study of individuals referred to a cardiovascular disease clinic designed for patients with long COVID

Scientists discuss the characteristics, diagnostic evaluations, and cardiac diagnoses in patients referred to a clinic designed for patients with PASC.

Omicron binds to ACE2 with high affinity, enhancing its transmissibility and infectivity

Does a COVID-19 vaccine booster improve the immune response of a poor responder?

A new study has focussed on determining the levels of nAb in individuals who received the second and third doses of the RNA vaccines developed by Pfizer and Moderna.

SARS-CoV-2 surveillance in urban wildlife from Ontario and Québec

Researchers conducted SARS-CoV-2 surveillance in urban wildlife from Ontario and Québec, Canada.

Inequalities of the US COVID-19 vaccination drive

The percentage of individuals with at least one dose of a COVID-19 vaccine, by communities, were collected from eight cities to determine US vaccine inequality.

Forecasting outbreak of SARS-CoV-2 Omicron variant with Tajima's D

A new study argues that that rapid genomic sequence surveillance is absolutely crucial and Tajima D tests should be included to predict future COVID-19 outbreaks.

Evaluating comparative effectiveness of Pfizer-BioNtech and Moderna vaccines among US veterans

A new study provided evidence of a lower 24-week risk of COVID-19–related outcomes among recipients of the mRNA-1273 vaccine, compared to their counterparts who received the BNT162b2 vaccine.